Angle (AGL)

Sector:

Support

Index:

FTSE AIM All-Share

14.00p
   
  • Change Today:
      0.25p
  • 52 Week High: 31.40
  • 52 Week Low: 9.25
  • Currency: UK Pounds
  • Shares Issued: 260.58m
  • Volume: 659,855
  • Market Cap: £36.48m
  • RiskGrade: 312
  • Beta: 0.05

ANGLE confirms recent positive Parsortix tests

By Josh White

Date: Friday 08 Dec 2017

LONDON (ShareCast) - (ShareCast News) - Liquid biopsy company ANGLE announced on Friday that the University of Southern California's Norris Comprehensive Cancer Center has presented results of extensive work with its 'Parsortix' system at the San Antonio Breast Cancer Symposium, detailing how the system could be used to obtain comparable gene expression information from a simple blood test in place of an invasive solid tissue biopsy of a metastatic site.
The AIM-traded firm said USC had made a direct comparison of extensive gene expression information from the biopsy of the metastatic site with that from a blood test processed with the Parsortix system.

Information from the blood test using the Parsortix system "did not show significantly different patterns of expression" compared to the invasive biopsy of the metastatic site.

It said 66 clinically-actionable genes in seven different signalling pathways were measured, addressing the key areas that clinicians currently investigate.

ANGLE said it was working towards an FDA clearance of the Parsortix system in metastatic breast cancer, with the required analytical and clinical studies targeted for completion by 30 June next year.

The company explained that it was seeking to become the first company ever to receive FDA clearance for a medical device to harvest cancer cells from patient blood for subsequent analysis.

It claimed the "groundbreaking" work presented by USC at San Antonio demonstrated the importance of being able to harvest and analyse those cells from patient blood.

"USC's groundbreaking work with ANGLE's Parsortix system over the last two years has delivered convincing data that a simple blood test may be able to provide all the clinical information traditionally provided by the invasive, expensive solid biopsy," said ANGLE founder and chief executive Andrew Newland.

"This is great news for ANGLE as it gives a clear guide to the importance of being able to harvest and analyse these cells from patient blood."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Angle Market Data

Currency UK Pounds
Share Price 14.00p
Change Today 0.25p
% Change 1.82 %
52 Week High 31.40
52 Week Low 9.25
Volume 659,855
Shares Issued 260.58m
Market Cap £36.48m
Beta 0.05
RiskGrade 312

Angle Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
8.3% below the market average8.3% below the market average8.3% below the market average8.3% below the market average8.3% below the market average
40.00% above the sector average40.00% above the sector average40.00% above the sector average40.00% above the sector average40.00% above the sector average
Price Trend
45.91% below the market average45.91% below the market average45.91% below the market average45.91% below the market average45.91% below the market average
64% below the sector average64% below the sector average64% below the sector average64% below the sector average64% below the sector average
Income Not Available
Growth
13.9% below the market average13.9% below the market average13.9% below the market average13.9% below the market average13.9% below the market average
11.11% below the sector average11.11% below the sector average11.11% below the sector average11.11% below the sector average11.11% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Angle Dividends

No dividends found

Trades for 01-May-2024

Time Volume / Share Price
15:10 30,000 @ 14.00p
13:31 3,280 @ 13.72p
12:39 666 @ 13.60p
12:18 50,000 @ 13.73p
12:12 40,000 @ 13.70p

Angle Key Personnel

CEO Andrew D Newland
Finance Director Ian F Griffiths
Chair Jan Groen

Top of Page